{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:40:15Z","timestamp":1782124815397,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.ctrv.2006.10.005","type":"journal-article","created":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T12:58:09Z","timestamp":1169557089000},"page":"161-176","source":"Crossref","is-referenced-by-count":44,"title":["Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario"],"prefix":"10.1016","volume":"33","author":[{"given":"Matthew C.","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam E.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph M.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctrv.2006.10.005_bib1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.10.005_bib2","doi-asserted-by":"crossref","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. New Engl J Med 1993;329(14):987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"issue":"5 Suppl. 5","key":"10.1016\/j.ctrv.2006.10.005_bib3","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2006.10.005_bib4","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2006.10.005_bib5","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","article-title":"New treatment options have changed the survival of patients with follicular lymphoma","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.10.005_bib6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2006.10.005_bib7","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2006.10.005_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","article-title":"The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2006.10.005_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ctrv.2006.10.005_bib10","first-page":"228","article-title":"Hematology Disease Site Group. Use of rituximab in the treatment of lymphoma: an evidence summary","volume":"6","author":"Imrie","year":"1999","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2006.10.005_bib11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.ctrv.2006.10.005_bib12","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.16.16","article-title":"Intensified CHOP with rituximab for intermediate or high-risk non-Hodgkin\u2019s lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma Groups [abstract]","volume":"106","author":"Sonneveld","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.13.13","article-title":"German High-Grade Non-Hodgkin Lymphoma Study Group. Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the RICOVER-60 trial of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL) [abstract]","volume":"106","author":"Pfreundschuh","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.005_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2006.10.005_bib16","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2006.10.005_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.2005.05827.x","article-title":"Randomized comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34+ cell enrichment device","volume":"132","author":"van Heeckeren","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.300.300","article-title":"Final analysis of a randomized, phase III, trial using etoposide and G-CSF with or without rituximab (R) for peripheral stem cell mobilization (PSC) in B-cell non-Hodgkin lymphoma (B-NHL) [abstract]","volume":"106","author":"Pohlman","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.677.677","article-title":"Rituximab vs. observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma: final analysis of the LNH98-B3 GELA study [abstract]","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2006.10.005_bib20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2006.10.005_bib21","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2431.2431","article-title":"Is first line single agent rituximab the best treatment for indolent non-Hodgkin\u2019s lymphoma? Update of a multicentric study comparing rituximab vs. CNOP vs. rituximab plus CNOP [abstract]","volume":"106","author":"Rivas-Vera","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin\u2019s lymphoma (NHL) and mantle-cell-lymphoma (MCL) [abstract]","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"issue":"18 Suppl.","key":"10.1016\/j.ctrv.2006.10.005_bib24","article-title":"Update of the FL2000 randomzied trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts) [abstract]","volume":"24","author":"Foussard","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.162.162","article-title":"Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphoplasmocytoid\/ic immunocytoma (LP-IC) \u2013 results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]","volume":"104","author":"Buske","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ctrv.2006.10.005_bib26","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2006.10.005_bib27","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.353.353","article-title":"EORTC Lymphoma Group. Chimeric anti-CD20 monoclonal antibody (rituximab;Mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: Final analysis of a phase III randomized Intergroup clinical trial [abstract]","volume":"106","author":"Van Oers","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.349.349","article-title":"Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]","volume":"106","author":"Hochster","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ctrv.2006.10.005_bib30","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2006.10.005_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2006.10.005_bib32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma \u2013 a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2006.10.005_bib33","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"18 Suppl.","key":"10.1016\/j.ctrv.2006.10.005_bib34","first-page":"422s","article-title":"Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]","volume":"24","author":"Dreyling","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"issue":"18","key":"10.1016\/j.ctrv.2006.10.005_bib35","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2006.10.005_bib36","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: diffuse large B-cell lymphoma","volume":"23","author":"Coiffier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2006.10.005_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2006.05975.x","article-title":"Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease","volume":"133","author":"Seyfarth","year":"2006","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.351.351","article-title":"Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis [abstract]","volume":"106","author":"Schulz","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2006.10.005_bib39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.350.350","article-title":"Mabthera (rituximab) plus CVP chemotherapy for first-line treatment of stage III\/IV follicular non-Hodgkin\u2019s lymphoma (NHL): confirmed efficacy with longer follow-up [abstract]","volume":"106","author":"Solal-C\u00e9ligny","year":"2005","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2006.10.005_bib40","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"37","key":"10.1016\/j.ctrv.2006.10.005_bib41","doi-asserted-by":"crossref","DOI":"10.3310\/hta8370","article-title":"Rituximab (MabThera) for aggressive non-Hodgkin\u2019s lymphoma: systematic review and economic evaluation","volume":"8","author":"Knight","year":"2004","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.ctrv.2006.10.005_bib42","doi-asserted-by":"crossref","DOI":"10.3310\/hta6030","article-title":"Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin\u2019s lymphoma: systematic review and economic evaluation","volume":"6","author":"Wake","year":"2002","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.ctrv.2006.10.005_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/JCO.2005.06.179","article-title":"Practitioners as experts: the influence of practicing oncologists \u201cin-the-field\u201d on evidence-based guideline development","volume":"23","author":"Browman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2006.10.005_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin\u2019s lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Ann Hematol"},{"issue":"16 Suppl.","key":"10.1016\/j.ctrv.2006.10.005_bib45","article-title":"Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma \u2013 follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]","volume":"23","author":"Dreyling","year":"2005","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1016\/j.ctrv.2006.10.005_bib46","unstructured":"European Organisation for Research and Treatment of Cancer (EORTC). Rituximab maintenance therapy dramatically improves survival for patients with lymphoma: EORTC 20981 trial demonstrates: risk of death can be halved [monograph on the Internet]. Brussels: EORTC AISBL\/IVZW; 2006 [2006 May 02]. Available from: <http:\/\/www.eortc.be\/Services\/doc\/web_release_rituximab_14_02_2006.htm>."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206002076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737206002076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T21:30:25Z","timestamp":1587331825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737206002076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0305737206002076"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2006.10.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}